TNF and pneumocystosis: In the UK, data from the British Society for Rheumatology Biologics Register for RA were analyzed regarding incidence of PCP, which was reported to range from 1.1 (with traditional synthetic DMARDs) to 2.0 (with anti-TNF biologics) per 10,000 patient-years [40].